Search Results for ""

Initially approved in 2018, talazoparib (Talzenna^®) capsules are indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene HER2-negative locally advanced or metastatic breast cancer.

In a clinical trial of 65 patients with metastatic or recurrent Merkel cell carcinoma who had not previously received systemic therapy for advanced disease, treatment with retifanlimab-dlwr (Zynyz^™) achieved a 52% overall response rate and 18% complete response rate, leading the U.S. Food and Drug Administration to grant it accelerated approval in March 2023.

Since the first bispecific antibody (BsAb), blinatumomab, received U.S. Food and Drug Administration approval in 2014, the drug class has developed exponentially, with the majority of currently approved agents entering clinical practice in the past two years. BsAbs are very effective for treating certain malignancies, including multiple myeloma and leukemia, and most are approved for oncology indications. Here’s what makes BsAbs different than other cancer treatments and the key considerations for oncology nursing clinical practice.

This ONS resource was produced for educational purposes only. Refer to the full talquetamab-tgvs (Talvey^™) package insert for all details.

Elranatamab-bcmm, an immunotherapy indicated for relapsed or refractory multiple myeloma, received accelerated approval in 2023. It is a bispecific antibody and T-cell engager that binds to BCMA, which occurs on the surface of myeloma and other cells, and CD3, which occurs on T cells, causing cytokine release and myeloma cell lysis. This ONS resource was produced for educational purposes only. Refer to the full elranatamab-bcmm (Elrexfio^™) package insert for all details.

Margetuximab-cmkb (Margenza^®) received U.S. Food and Drug Administration approval in December 2020 for previously treated adults with metastatic HER2-positive breast cancer after clinical trials demonstrated increased progression-free and overall survival. 

After an open-label, multicenter, single-arm trial demonstrated a 56% objective response rate, with 43% achieving complete responses, and an estimated 18.4-month median duration of response, the U.S. Food and Drug Administration granted glofitamab-gxbm (Columvi™) accelerated approval in June 2023. 

Innovation—a proactive effort to create or build on ideas—is something that oncology nurses and advanced practice providers (APPs) do every day. This month’s 49th Annual ONS Congress^® reminds us to “ignite the extraordinary” and recognize how we can use our strengths to blaze new trails for oncology and health care. Step by step, we all have opportunities to innovate in oncology nursing through evidence-based practice, quality improvement, the development of new products and technology, and research.

The first innovation in stem cell mobilization for multiple myeloma in a decade, motixafortide (Aphexda^™) received U.S. Food and Drug Administration approval on September 11, 2023. The drug’s clinical trial demonstrated that one dose of motixafortide plus filgrastim enabled a majority of patients to achieve the collection goal of at least six million hematopoietic stem cells.